The paradoxical activation of RAF–MEK–ERK signaling leads to both the intrinsic resistance in Ras-mutated cancers and the acquired resistance in BRAFV600E-driven cancers, which severely limits the efficacy of RAF inhibitors in cancer therapy (32). Here, RAF1 is linked to cancer.